Post-Doctoral Fellow - Real-World Evidence, Epidemiology, & Health Economics And Outcomes Research
Current-Generate and manage evidence gaps and appropriate study tactics for oncology therapeutic area (TA) assets including Onivyde, Cabometyx, Somatuline, and Tazverik-Develop integrated evidence generation plans (IEGPs) for multiple oncology products, coordinating cross-functional teams to shape strategies over a 5-year timeline-Design and lead real-world evidence (RWE) studies in conceptualization, protocol writing, and publication strategy to demonstrate value and inform clinical practice for companywide oncology and rare disease portfolios-Design and implement global and US medical affairs (GMA, USMA) strategies for indication expansion, clinical guidance development, medical communications, dataset selection, key-opinion leader (KOL) engagement, and study design-Guide RWE study protocols through the evidence generation review board (EGRB) internal review process, securing endorsement-Synthesize payer-relevant and clinical information into systematic literature reviews (SLRs), targeted literature reviews (TLRs), meta-analyses, and indirect treatment comparisons across multiple indications and TAs for internal partners and stakeholders-Advise on GMA strategy efforts, leveraging knowledge and expertise in health economics and outcomes research (HEOR) models, dossiers, budget impact models (BIM), cost-effectiveness models (CEM), health technology assessments (HTA), health state diagrams, and decision trees-Design, implement, and lead epidemiologic investigations, supporting forecasting, market access, HEOR, USMA, GMA, business development (BD), global patient safety (GPS), research and development (R&D), and global regulatory affairs (GRA)-Forecast market potential based on epidemiological data within the oncology, rare disease, and neurology TAs subsequently leading to the commercialization of Ojemda-Manage and execute clinical and payer strategies using real-world data (RWD) to quantify asset value for four oncology products across four indications
